6th February 2024

Homocystinuria

Homocystinuria is a group of disorders characterised by impaired breakdown of amino acid methionine. Most typically, this is due to an autosomal recessive abnormality that results in deficiencies in the enzymes involved in methionine metabolism, such as cystathionine B synthase, methionine synthase and methylenetetrahydrofolate reductase. Cystathionine b synthase usually catalyses the breakdown of methionine by catalysing the conversion of homocysteine (an intermediary) to cystathionine. Reduced enzyme activity results in homocysteine and methionine accumulation. Elevated levels of both substances cause various complications, including eye and skeletal abnormalities, cardiovascular issues, intellectual disability and increased risk of blood clots. 

Clinical features 

The clinical features of homocystinuria are varied, often dependent on the specific enzyme deficiency and severity of the condition, but include:

• Intellectual disability: 
  • Elevated homocysteine levels can affect brain development, leading to intellectual disability and learning difficulties. Some patients may also develop seizures and psychiatric conditions.
• Eye abnormalities:
  • Near-sightedness (myopia), dislocation of the lens of the eye, increased risk of glaucoma and spontaneous retinal detachment
• Skeletal abnormalities:
  • Marfanoid features include tall stature and long limbs, curvature of the spine (scoliosis), chest deformities, osteoporosis and joint problems 
• Cardiovascular complications: 
  • Increased risk of cardiovascular problems, including blood clots, heart attacks, strokes and atherosclerosis.
• Other features: 
  • Some individuals with homocystinuria may exhibit a pale complexion, thin hair, brittle bones, and a tendency to form kidney stones.

Diagnosis 

Newborns with this condition are usually diagnosed through the newborn screening programme, but cases may be suspected based on clinical symptoms. Irrespective, follow-up confirmatory tests are required, which use blood and urine samples to detect elevated homocysteine and genetic testing to characterise the specific defect causing a particular enzyme deficiency.

Management

Early detection is crucial, particularly the early testing of siblings of affected individuals. 

The mainstay of management relies on maintaining homocysteine levels within the normal range, minimising symptoms and preventing associated long-term complications. This involves adherence to a low methionine diet and restricting meat, fish, eggs, dairy products and certain grains, all of which are methionine rich. In addition, pyridoxine supplements are said to be effective in around 50% of individuals with this condition, enhancing the activity of enzymes involved in methionine metabolism. Some variants are also responsive to supplementation with folate, vitamin B12 or betaine, which support the breakdown of homocysteine.

In other cases, additional medications may be prescribed to manage the risk of complications, such as anticoagulation to prevent thromboses. Affected individuals require lifelong management with continuous monitoring of homocysteine levels and other blood markers to assess treatment efficacy with necessary adjustments to dietary and treatment regimens where levels remain high. Effective management should involve close coordination of care with a metabolic specialist, and a multidisciplinary healthcare team is crucial for optimal care and prevention of complications.